Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy

References

• Mac BrideMBRhodesDJShusterLTVulvovaginal atrophyMayo Clin Proc2010851879420042564
   PubMed Web of Science ®Google Scholar
• PortmanDJGassMLVulvovaginal Atrophy Terminology Consensus Conference PanelGenitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause SocietyClimacteric201417555756325153131
   PubMed Web of Science ®Google Scholar
• DavilaGWSinghAKarapanagiotouIAre women with urogenital atrophy symptomatic?Am J Obstet Gynecol2003188238238812592244
   PubMed Web of Science ®Google Scholar
• StoneSCMickalARyePHPostmenopausal symptomatology, maturation index, and plasma estrogen levelsObstet Gynecol19754566256271095996
   PubMed Web of Science ®Google Scholar
• GassMLCochraneBBLarsonJCPatterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women’s Health InitiativeMenopause201118111160117121983008
   PubMed Web of Science ®Google Scholar
• HuangAJMooreEEBoykoEJVaginal symptoms in postmenopausal women: self-reported severity, natural history, and risk factorsMenopause201017112112619574936
   PubMed Web of Science ®Google Scholar
• PalaciosSAdvances in hormone replacement therapy: making the menopause manageableBMC Womens Health200882219038018
   PubMedGoogle Scholar
• HsiaJSimonJALinFPeripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement StudyCirculation2000102182228223211056097
   PubMed Web of Science ®Google Scholar
• RossouwJEAndersonGLPrenticeRLRisks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trialJAMA2002288332133312117397
   PubMed Web of Science ®Google Scholar
• RobertsHManaging the menopauseBMJ2007334759673674117413174
   PubMed Web of Science ®Google Scholar
• NotelovitzMLenihanJPMcDermottMKerberIJNanavatiNArceJInitial 17 beta-estradiol dose for treating vasomotor symptomsObstet Gynecol200095572673110775738
   PubMed Web of Science ®Google Scholar
• UtianWHShoupeDBachmannGPinkertonJVPickarJHRelief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetateFertil Steril20017561065107911384629
   PubMed Web of Science ®Google Scholar
• SturdeeDWPanayNInternational Menopause Society Writing GroupRecommendations for the management of postmenopausal vaginal atrophyClimacteric201013650952220883118
   PubMed Web of Science ®Google Scholar
• SimonJAIdentifying and treating sexual dysfunction in postmenopausal women: the role of estrogenJ Womens Health (Larchmt)201120101453146521819250
   PubMed Web of Science ®Google Scholar
• SucklingJLethabyAKennedyRLocal oestrogen for vaginal atrophy in postmenopausal womenCochrane Database Syst Rev20064CD001500
   PubMedGoogle Scholar
• ReesMPerez-LopezFRCeasuIEMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophyMaturitas201273217117422818886
   PubMed Web of Science ®Google Scholar
• Al-BaghdadiOEwiesAATopical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overviewClimacteric200912291105
   PubMed Web of Science ®Google Scholar
• SantenRJAllredDCArdoinSPPostmenopausal hormone therapy: an Endocrine Society scientific statementJ Clin Endocrinol Metab2010957 Suppl 1s1s6620566620
   PubMed Web of Science ®Google Scholar
• LabrieFCusanLGomezJLEffect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal womenMenopause2009161303618820592
   PubMed Web of Science ®Google Scholar
• Eugster-HausmannMWaitzingerJLehnickDMinimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tabletsClimacteric201013321922720423242
   PubMed Web of Science ®Google Scholar
• No authors listedManagement of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause SocietyMenopause201320988890223985562
   PubMed Web of Science ®Google Scholar
• Sanchez-BorregoRManubensMNavarroMCPosition of the Spanish Menopause Society regarding vaginal health care in postmenopausal womenMaturitas201478214615024720907
   PubMed Web of Science ®Google Scholar
• CanoAEstevezJUsandizagaRThe therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III studyMenopause201219101130113922914208
   PubMed Web of Science ®Google Scholar
• SantoroNKomiJPrevalence and impact of vaginal symptoms among postmenopausal womenJ Sex Med2009682133214219493278
   PubMed Web of Science ®Google Scholar
• NappiREKokot-KierepaMVaginal Health: Insights, Views & Attitudes (VIVA) – results from an international surveyClimacteric2012151364422168244
   PubMed Web of Science ®Google Scholar
• SievertLLSalibaMReherDThe medical management of menopause: a four-country comparison care in urban areasMaturitas200859172118178044
   PubMed Web of Science ®Google Scholar
• Sanchez-BorregoRMendozaNBeltranEPosition of the Spanish Menopause Society regarding the management of menopausal symptoms in breast cancer patientsMaturitas201375329430023706280
   PubMed Web of Science ®Google Scholar
• BigliaNPeanoESgandurraPLow-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary studyGynecol Endocrinol201026640441220196634
   PubMed Web of Science ®Google Scholar
• PalaciosSManaging urogenital atrophyMaturitas200963431531819493638
   PubMed Web of Science ®Google Scholar
• HainerBLGibsonMVVaginitisAm Fam Physician201183780781521524046
   PubMed Web of Science ®Google Scholar
• ChenJGengLSongXLiHGiordanNLiaoQEvaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trialJ Sex Med20131061575158423574713
   PubMed Web of Science ®Google Scholar
• TedeschiCBenvenutiCResearch Group EGComparison of vaginal gel isoflavones versus no topical treatment in vaginal dystrophy: results of a preliminary prospective studyGynecol Endocrinol201228865265422316315
   PubMed Web of Science ®Google Scholar
• GhazanfarpourMLatifnejad RoudsariRTregliaGSadeghiRTopical administration of isoflavones for treatment of vaginal symptoms in postmenopausal women: a systematic review of randomised controlled trialsJ Obstet Gynaecol201535878378725710207
   PubMedGoogle Scholar
• PinkertonJVStanczykFZClinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophyMenopause201421330931923777900
   PubMed Web of Science ®Google Scholar
• BerrodinTJChangKCKommBSFreedmanLPNagpalSDifferential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combinationMol Endocrinol2009231748519036900
   PubMedGoogle Scholar
• KatzenellenbogenBSKatzenellenbogenJABiomedicine. Defining the “S” in SERMsScience200229555642380238111923515
   PubMed Web of Science ®Google Scholar
• KharodeYBodinePVMillerCPLyttleCRKommBSThe pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis preventionEndocrinology2008149126084609118703623
   PubMed Web of Science ®Google Scholar
• KommBSA new approach to menopausal therapy: the tissue selective estrogen complexReprod Sci2008151098499219088368
   PubMed Web of Science ®Google Scholar
• MartinkovichSShahDPlaneySLArnottJASelective estrogen receptor modulators: tissue specificity and clinical utilityClin Interv Aging201491437145225210448
   PubMed Web of Science ®Google Scholar
• GoldsteinSRSiddhantiSCiacciaAVPlouffeLJrA pharmacological review of selective oestrogen receptor modulatorsHum Reprod Update20006321222410874566
   PubMed Web of Science ®Google Scholar
• TeeMKRogatskyITzagarakis-FosterCEstradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and betaMol Biol Cell20041531262127214699072
   PubMed Web of Science ®Google Scholar
• TaylorHSDesigning the ideal selective estrogen receptor modulator – an achievable goal?Menopause200916360961519182697
   PubMed Web of Science ®Google Scholar
• ShanleEKXuWSelectively targeting estrogen receptors for cancer treatmentAdv Drug Deliv Rev201062131265127620708050
   PubMed Web of Science ®Google Scholar
• MaximovPYLeeTMJordanVCThe discovery and development of selective estrogen receptor modulators (SERMs) for clinical practiceCurr Clin Pharmacol20138213515523062036
   PubMedGoogle Scholar
• DaviesGCHusterWJLuYPlouffeLJrLakshmananMAdverse events reported by postmenopausal women in controlled trials with raloxifeneObstet Gynecol199993455856510214833
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyFareston Summary of Product CharacteristicsEMA2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000091/WC500020689.pdfAccessed June 1, 2016
   Google Scholar
• European Medicines AgencyConbriza Summary of Product CharacteristicsEMA2011 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000913/WC500033577.pdfAccessed June 1, 2016
   Google Scholar
• DelmantoANahas-NetoJNahasEAde OliveiraMLFernandesCETraimanPEffect of raloxifene on the vaginal epithelium of postmenopausal womenEur J Obstet Gynecol Reprod Biol2008139218719218400357
   PubMed Web of Science ®Google Scholar
• KomiJLankinenKSDeGregorioMEffects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal womenJ Bone Miner Metab200624431431816816926
   PubMed Web of Science ®Google Scholar
• MarttunenMBCacciatoreBHietanenPProspective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal womenBr J Cancer200184789790211286468
   PubMed Web of Science ®Google Scholar
• VardyMDLindsayRScottiRJShort-term urogenital effects of raloxifene, tamoxifen, and estrogenAm J Obstet Gynecol20031891818812861143
   PubMed Web of Science ®Google Scholar
• VarrasMPolyzosDAkrivisCHEffects of tamoxifen on the human female genital tract: review of the literatureEur J Gynaecol Oncol2003243–425826812807236
   PubMed Web of Science ®Google Scholar
• PolinSAAscherSMThe effect of tamoxifen on the genital tractCancer Imaging2008813514518603495
   PubMed Web of Science ®Google Scholar
• ParsonsAMerrittDRosenAEffect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophyObstet Gynecol2003101234635212576260
   PubMed Web of Science ®Google Scholar
• PinkertonJVShifrenJLLa ValleurJRosenARoesingerMSiddhantiSInfluence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal womenMenopause2003101455212544676
   PubMed Web of Science ®Google Scholar
• KaganRThe tissue selective estrogen complex: a novel approach to the treatment of menopausal symptomsJ Womens Health (Larchmt)201221997598122759213
   PubMed Web of Science ®Google Scholar
• LoboRAPinkertonJVGassMLEvaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profileFertil Steril20099231025103819635615
   PubMed Web of Science ®Google Scholar
• KaganRWilliamsRSPanKMirkinSPickarJHA randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal womenMenopause201017228128919779382
   PubMed Web of Science ®Google Scholar
• CuiYZongHYanHLiNZhangYThe efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysisJ Sex Med201411248749724251418
   PubMed Web of Science ®Google Scholar
• VoipioSKKomiJKangasLHalonenKDeGregorioMWErkkolaRUEffects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal womenMaturitas200243320721412443837
   PubMed Web of Science ®Google Scholar
• KangasLUnkilaMTissue selectivity of ospemifene: pharmacologic profile and clinical implicationsSteroids20137812–131273128024055829
   PubMed Web of Science ®Google Scholar
• QuQZhengHDahllundJSelective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized ratsEndocrinology2000141280982010650964
   PubMed Web of Science ®Google Scholar
• TarasTLWurzGTDeGregorioMWIn vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancerJ Steroid Biochem Mol Biol2001774–527127911457665
   PubMed Web of Science ®Google Scholar
• European Medicines AgencySenshio: European Public Assessment ReportReport No: EMEA/H/C/002780/0000London (UK)European Medicines Agency2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002780/WC500182777.pdfAccessed June 1, 2016
   Google Scholar
• BachmannGAKomiJOOspemifene Study GroupOspemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 studyMenopause201017348048620032798
   PubMed Web of Science ®Google Scholar
• PortmanDPalaciosSNappiREMueckAOOspemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trialMaturitas2014782919824679891
   PubMed Web of Science ®Google Scholar
• PortmanDJBachmannGASimonJAOspemifene Study GroupOspemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophyMenopause201320662363023361170
   PubMed Web of Science ®Google Scholar
• GoldsteinSRBachmannGAKoninckxPROspemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophyClimacteric201417217318223984673
   PubMed Web of Science ®Google Scholar
• SimonJALinVHRadovichCBachmannGAOspemifene Study GroupOne-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterusMenopause201320441842723096251
   PubMed Web of Science ®Google Scholar
• SimonJPortmanDMabeyRGJrOspemifene Study GroupLong-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal womenMaturitas201477327428124411556
   PubMed Web of Science ®Google Scholar
• SoeLHWurzGTKaoCJDeGregorioMWOspemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breastInt J Womens Health2013560561124109197
   PubMedGoogle Scholar
• NappiREPanayNBruyniksNCastelo-BrancoCDe VilliersTJSimonJAThe clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophyClimacteric201518223324025335119
   PubMed Web of Science ®Google Scholar
• ConstantineGGrahamSKoltunWDKingsbergSAAssessment of ospemifene or lubricants on clinical signs of VVAJ Sex Med20141141033104124443923
   PubMed Web of Science ®Google Scholar
• ConstantineGGrahamSPortmanDJRosenRCKingsbergSAFemale sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trialClimacteric201518222623225252699
   PubMed Web of Science ®Google Scholar
• EttingerBHaitHReapeKZShuHMeasuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approachMenopause200815588588918779677
   PubMed Web of Science ®Google Scholar
• NappiREPalaciosSImpact of vulvovaginal atrophy on sexual health and quality of life at postmenopauseClimacteric201417139
   PubMed Web of Science ®Google Scholar
• ConstantineGDGoldsteinSRArcherDFEndometrial safety of ospemifene: results of the phase 2/3 clinical development programMenopause2015221364324977459
   PubMed Web of Science ®Google Scholar
• ChristiansenCChesnutCH3rdAdachiJDSafety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosisBMC Musculoskelet Disord20101113020569451
   PubMed Web of Science ®Google Scholar
• GradyDEttingerBMoscarelliESafety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluationObstet Gynecol2004104483784415458908
   PubMed Web of Science ®Google Scholar
• GennariLMerlottiDValleggiFNutiROspemifene use in postmenopausal womenExpert Opin Investig Drugs2009186839849
   PubMed Web of Science ®Google Scholar
• KingsbergSAWysockiSMagnusLKrychmanMLVulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) surveyJ Sex Med20131071790179923679050
   PubMed Web of Science ®Google Scholar
• ParishSJNappiREKrychmanMLImpact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophyInt J Womens Health2013543744723935388
   PubMedGoogle Scholar
• DeGregorioMWZerbeRLWurzGTOspemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophySteroids201490829325087944
   PubMed Web of Science ®Google Scholar
• European Medicines AgencySenshio Summary of Product CharacteristicsEMA2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002780/WC500182775.pdfAccessed June 1, 2016
   Google Scholar